SNAP25: Synaptosomal-associated protein 25
t-SNARE involved in the molecular regulation of neurotransmitter release.
- Drugs that act on it: 8
- Approved: 7
- In phases 1 to 3: 1
- Sponsors: 7
Who is on it, and how far along
Every drug ChEMBL records acting on SNAP25, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 2
- Other 6
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- AbbVie225%
- AEON Biopharma, Inc.113%
- Hugel113%
- Ipsen113%
- Medy-Tox113%
- Merz Group113%
- Revance Therapeutics113%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 8 act as: Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor; the rest name their own mechanism.| AbobotulinumtoxinaBoxed warning | Approved | Ipsen | Other | Inhibitor | 180 |
| Daxibotulinumtoxina | Approved | Revance Therapeutics | Other | Inhibitor | 180 |
| OnabotulinumtoxinaBoxed warning | Approved | AbbVie | Other | Inhibitor | 180 |
| Botulinum toxin type aBoxed warning | Approved | Medy-Tox | Protein or peptide | Hydrolytic enzymeSynaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | 178 |
| IncobotulinumtoxinaBoxed warning | Approved | Merz Group | Other | Inhibitor | 43 |
| Prabotulinumtoxin aBoxed warning | Approved | AEON Biopharma, Inc. | Other | Proteolytic enzymeSynaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme | 1 |
| Letibotulinumtoxina | Approved | Hugel | Other | Hydrolytic enzymeSynaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | 0 |
| Trenibotulinumtoxine | Phase 3 | AbbVie | Protein or peptide | Hydrolytic enzymeSynaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | 3 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov.| EndoFLIP-Guided Initial Management of Esophagogastric Junction Outflow Obstruction | Abobotulinumtoxina, Daxibotulinumtoxina, Onabotulinumtoxina, Botulinum toxin type a | Not applicable | Not yet recruiting | Hospital Clinic of Barcelona | Nov 10, 2026 |
| Can TrenibotulinumtoxinE Reverse OnabotulinumtoxinA Effect in Treating Lateral Canthal Lines? | Abobotulinumtoxina, Daxibotulinumtoxina, Onabotulinumtoxina, Botulinum toxin type a, Trenibotulinumtoxine | Phase 2 | Not yet recruiting | Project Skin MD | Nov 6, 2026 |
| Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris. | Abobotulinumtoxina, Daxibotulinumtoxina, Onabotulinumtoxina, Botulinum toxin type a | Phase 3 | Not yet recruiting | Cairo University | Nov 5, 2026 |
| Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury | Botulinum toxin type a | Phase 2 | Recruiting | Kessler Foundation | Oct 26, 2026 |
| Perineural Botulinum Toxin Injection Versus Oral Duloxetine in Relief of Foot Pain in Painful Peripheral Diabetic Neuropathy | Abobotulinumtoxina, Daxibotulinumtoxina, Onabotulinumtoxina, Botulinum toxin type a | Phase 2 | Not yet recruiting | Assiut University | Oct 20, 2026 |
| Cleft Lip Scarring After Botox | Abobotulinumtoxina, Daxibotulinumtoxina, Onabotulinumtoxina, Botulinum toxin type a | Phase 2 | Recruiting | Children's National Research Institute | Oct 19, 2026 |
| MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain | Abobotulinumtoxina, Daxibotulinumtoxina, Onabotulinumtoxina, Botulinum toxin type a | Phase 2 | Not yet recruiting | Weill Medical College of Cornell University | Oct 16, 2026 |
| Decision Regret Following Yonsei-Point Botulinum Toxin for Gummy Smile | Abobotulinumtoxina, Daxibotulinumtoxina, Incobotulinumtoxina, Onabotulinumtoxina, Botulinum toxin type a | — | Not yet recruiting | Cairo University | Oct 14, 2026 |
| Can Adjunctive Oral Magnesium Supplementation Prolong the Effect of Botulinum Toxin Type A in Excessive Gingival Display? | Abobotulinumtoxina, Daxibotulinumtoxina, Incobotulinumtoxina, Onabotulinumtoxina | Not applicable | Enrolling by invitation | Cairo University | Oct 14, 2026 |
| To Evaluate HU-045 With Moderate to Severe Glabellar Lines | Incobotulinumtoxina | Phase 3 | Recruiting | Huons Biopharma | Oct 13, 2026 |
| A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines | Trenibotulinumtoxine | Phase 2 | Recruiting | AbbVie | Oct 13, 2026 |
| Clinical Evaluation of Botulinum Toxin a in the Management of Temporomandibular Myofascial Pain | Incobotulinumtoxina | Phase 2 | Recruiting | Riphah International University | Sep 29, 2026 |
| Does Addition of Medial Pterygoid Muscle Injection Improve the Outcome of Botulinum Toxin Therapy for Masticatory Myofascial Pain Syndrome? | Incobotulinumtoxina | Not applicable | Not yet recruiting | Fayoum University | Aug 19, 2026 |
| A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants | Trenibotulinumtoxine | Phase 2 | Active, not recruiting | AbbVie | Jul 28, 2026 |
| Extracorporeal Shock Wave Therapy in Botulinum Toxin-Treated Patients With Post-Stroke Ankle Plantar Flexor Spasticity | Incobotulinumtoxina | Not applicable | Not yet recruiting | Pamukkale University | Jul 10, 2026 |
| Efficacy of Botulinum Toxin Versus Placebo on Pain and Health Related Quality of Life of Patients With Piriformis Muscle Syndrome | Incobotulinumtoxina | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nīmes | Jun 3, 2026 |
| Comparison of Concurrent Endoscopic Prostate Surgery With Botox-A Injection and Postoperative Medical Therapy in BPH Patients With Overactive Bladder Symptoms | Incobotulinumtoxina | — | Active, not recruiting | Taksim Egitim ve Arastirma Hastanesi | Apr 28, 2026 |
| BoTox Into the Sternocleidomastoid Muscles (SCM) | Prabotulinumtoxin a | Phase 4 | Recruiting | Boston Medical Center | Apr 1, 2025 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Congenital myasthenic syndrome
- 0.69
- Benign essential blepharospasm
- 0.54
- Spasticity
- 0.53
- Skin aging
- 0.53
- Botulism
- 0.51
- Urgency urinary incontinence
- 0.51
- Developmental and epileptic encephalopathy
- 0.50
- Cervical cancer
- 0.46
- Hereditary disease
- 0.46
- Seizure
- 0.44
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364159, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P60880, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets